Molecular Partners

Molecular Partners is developing a novel class of therapeutic proteins, termed DARPins. DARPins equal the target binding properties of antibodies but feature superior stability and are easier to express, thus allowing novel therapeutic approaches. To date, DARPins have been generated against a high number of targets, including cell surface receptors, cytokines, proteases, kinases and viral coat proteins.

The company was incorporated in 2004 as a spin-off company of the group of Professor Andreas Plückthun at the University of Zürich. Molecular Partners owns the exclusive commercial rights in DARPins and has a complete freedom to operate in the field.


Recent News

January 17, 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its

 
November 12, 2012
Molecular Partners enters into a strategic collaboration agreement with Boehringer Ingelheim to support its proprietary pipeline with clinical supply of DARPin® molecules

 
August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

 
May 31, 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

 
December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

 
April 28, 2011
Molecular Partners reports positive results from its first clinical studies

 
February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
September 1, 2010
Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum

 
December 15, 2009
Molecular Partners Secures CHF 46 Million in a Series B Financing

 
January 15, 2008
Molecular Partners AG collaborates with Centocor Research & Development, Inc.

 
August 14, 2007
Molecular Partners Raises 18.5 Mio CHF in Series A Financing

 


Company Info
 
Country: Switzerland
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Dr. Christian Zahnd, CEO; Andreas Emmenegger, CFO; Dr. Michael Stumpp, CSO; Dr. Patrick Amstutz, CBO


Company website
 www.molecularpartners.com


Endeavour Vision Team
 
Sven Lingjaerde
Olivier Valdenaire
© Endeavour Vision SA 2006-2013 Terms & Conditions